Skip to main content
Figure 3 | Critical Care

Figure 3

From: Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial

Figure 3

Critical illness polyneuropathy, myopathy and critical illness polyneuropathy and/or myopathy scores. Critical illness polyneuropathy and/or myopathy (CIPNM) severity sum score was not different on Day 14 between the intravenous immunoglobulin (IVIG) and placebo treatment group based on electrophysiological stimulation and muscle histology. CIPNM severity sum score deteriorated from baseline (Day 0) to Day 14 in both groups (a). Critical illness polyneuropathy ( CIP) was similar in the IVIG and placebo treatment group at all times based on electrophysiological stimulation (b). Critical illness myopathy (CIM) scores were similar in the two groups based on muscle histology (c). A two-sided P-value ≤0.05 was considered statistically significant (*).

Back to article page

Critical Care

ISSN: 1364-8535